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a  b  s  t  r  a  c  t
Chlamydia  trachomatis  replication  takes  place  inside  of  a  host  cell,  exclusively  within  a vacuole  known  as
the  inclusion.  During  an  infection,  the inclusion  expands  to accommodate  the  increasing  numbers  of C.
trachomatis.  However,  whether  inclusion  expansion  requires  bacterial  replication  and/or  de novo  protein
synthesis  has  not  been  previously  investigated  in  detail.  Therefore,  using  a chemical  biology  approach,  we
herein investigated  C.  trachomatis  inclusion  expansion  under  varying  conditions  in vitro.  Under  normal
cell  culture  conditions,  inclusion  expansion  correlated  with  C.  trachomatis  replication.  When  bacterialhemical biology
nclusion expansion
acterial replication
replication  was  inhibited  using  KSK120,  an  inhibitor  that  targets  C.  trachomatis  glucose  metabolism,
inclusions  expanded  even  in  the  absence  of  bacterial  replication.  In  contrast,  when  bacterial  protein
synthesis  was  inhibited  using  chloramphenicol,  expansion  of  inclusions  was  blocked.  Together,  these
data  suggest  that  de  novo  protein  synthesis  is  necessary,  whereas  bacterial  replication  is dispensable  for
C. trachomatis  inclusion  expansion.
© 2015  The  Authors.  Published  by  Elsevier  GmbH.  This  is  an  open  access  article  under  the  CCntroduction
Chlamydia trachomatis is the causative agent of several sexu-
lly transmitted diseases (Haggerty et al., 2010) as well as the eye
nfection trachoma (Burton and Mabey, 2009). Chlamydia is an obli-
ate intracellular bacterial pathogen that requires a eukaryotic host
ell to subsequently grow and develop. Within a eukaryotic cell,
hlamydia resides in a membrane-bound vacuole known as the
nclusion. Following invasion, Chlamydia alters the features of the
nternalized vacuole, which allows the bacteria to avoid degrada-
ion through the endocytic pathway (Fields and Hackstadt, 2002).
hroughout the course of infection the inclusion expands as the
umber of chlamydial cells increase. The inclusion expansion has
een suggested to be dependent on host cell lipid metabolism
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(Derre et al., 2011; Robertson et al., 2009), host cell cytoskeletal
proteins, vimentin and actin (Kumar and Valdivia, 2008a), and
secreted bacterial effector proteins (Jorgensen and Valdivia, 2008;
Mital et al., 2013), which may  manipulate processes in the host
cytoplasm that are required for optimal inclusion expansion. It
is possible that expansion of the chlamydial inclusion is linked
to bacterial replication (Fields and Hackstadt, 2002; Kumar and
Valdivia, 2008b), and in fact, inclusion area has been used to indi-
rectly measure chlamydial replication and growth (Engström et al.,
2013; Nguyen et al., 2011; Tietzel et al., 2009; Volceanov et al.,
2014). However, a potential link between inclusion expansion and
bacterial replication has not been proven experimentally or char-
acterized under different growth conditions.
Acquisition of host cell metabolites is critical for chlamydial
intracellular growth and development. Host cell glucose-6-
phosphate (G-6P) appears to be important for C. trachomatis
infectivity (Iliffe-Lee and McClarty, 2000; Omsland et al., 2012,
2014; Saka et al., 2011), and recently we  identiﬁed an inhibitor,
KSK120, which is a 2-pyridone inhibitor that blocks C. trachomatis
infectivity by affecting its G-6P metabolism. Current data indicate
that the G-6P transporter UhpC is targeted by KSK120 and that this
compound may  block import of G-6P into C. trachomatis. Moreover
s article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
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nd interestingly, we also observed that KSK120 might decrease
acterial replication without affecting the expansion of formed C.
rachomatis inclusions (Engström et al., 2015). Thus, to potentially
eveal novel insights on the regulation of inclusion expansion, we
ave further characterized the effect of compound KSK120 on C.
rachomatis infections.
aterial and methods
ell culture, bacterial infections and compound KSK120
The HeLa cell line (DSMZ) was grown at 37 ◦C (5% CO2) in
PMI 1640 (Sigma) supplemented with 10% FBS (Sigma) and
0 mM HEPES. Chlamydia trachomatis serovar LGV-L2 454/Bu (ATCC
R902B) and C. trachomatis serovar D were grown in HeLa cells
nd elementary bodies were puriﬁed as previously described by
aldwell et al. (1981) and stored in SPG buffer (0.25 M sucrose,
0 mM sodium phosphate, 5 mM l-glutamic acid). For infection
xperiments, HeLa cells were infected with C. trachomatis diluted
n Hanks balance salt solution (HBSS) (GIBCO®, Invitrogen) with
 multiplicity of infection (MOI) of 0.5 for 1 h at 37 ◦C (5% CO2).
ubsequently HBSS was removed and complete RPMI media sup-
lemented with compound KSK120 or DMSO was  added to the
nfected cells. Cycloheximide was excluded in all experiments.
SK120 was synthesized and handled as previously described
Engström et al., 2015). KSK120 was dissolved in dimethyl sulfox-
de (DMSO, Sigma) to a ﬁnal concentration of 20 mM,  and stored at
oom temperature unexposed to light for a period of up to 2 months.
rior to the experiments, compounds were diluted in pre-warmed
PMI media to a concentration of 10 M.  Dilution of KSK120 in
re-warmed media is necessary to avoid compound aggregation.
hloramphenicol (Cml, Sigma) was dissolved in water to a ﬁnal con-
entration of 20 mg/ml. At 24 hpi, media without Cml  was removed
rom infected cells and subsequently replaced with fresh media
ontaining 200 g/ml Cml.
etermination of C. trachomatis inclusion size and C.
rachomatis replication
At varying time points, postinfection, media was  completely
emoved and infected cells were washed once in PBS before ﬁx-
tion in 100% methanol (room temperature) for 5 min. Background
uorescence signals were reduced by blocking the samples with
% BSA for 1 h. Next, samples were incubated with primary anti-
ajor outer membrane (MOMP) antibody (gift from Ken Fields)
nd primary anti-heat shock protein 60 (Hsp60) antibody (Santa
ruz Biotechnology). An LRSC-conjugated anti-rabbit antibody
nd a FITC-conjugated anti-mouse antibody (both from Jackson
mmunoResearch Laboratories) were used as secondary antibod-
es against MOMP  and Hsp60, respectively. DNA was stained with
00 nM 4′,6-diamidino-2-phenylindole (DAPI). Coverslips were
ounted on glass slides with ﬂuorescence mounting media (Dako).
mages were obtained using confocal laser scanning microscopy
sing identical settings (Nikon Eclipse C1 plus). Identical contrast
djustments of images were carried out using Adobe Photoshop
oftware (Adobe Systems Inc.). Inclusion areas were measured from
cquired confocal transmission images that were processed using
Z-C1 software (Nikon), as previously described (Engström et al.,
013). Representative data are from one hundred C. trachomatis
nclusions. C. trachomatis replication was determined by Real-Time
uantitative PCR (qPCR) (iQ5 Real-Time PCR Detection System; Bio-
ad Laboratories), using SYBR-green chemistry (WWR). A total of
0 ng of DNA template were used in all qPCR reactions, and all
amples were run in triplicate (Engström et al., 2010). Primers
mplifying omcB were used to quantify C. trachomatis genomicdical Microbiology 305 (2015) 378–382 379
DNA and primers amplifying gapdh were used to quantify host cell
genomic DNA. Subsequently, C. trachomatis DNA was normalized
against host cell DNA (Ouellette et al., 2006), and DMSO treated
infections were arbitrarily set to 1. DNA was isolated from three
independent experiments.
Results and discussion
C. trachomatis replication and inclusion expansion are impaired
to varying extents by compound KSK120
We recently observed that KSK120-treatment altered the dis-
tribution of C. trachomatis serovar LGV-2 within the inclusion. The
usual homogeneous distribution of C. trachomatis serovar LGV-2
becomes patchy, lacking uniformity (Fig. 1A). This observed effect
was not accompanied by a change in the size or morphology of indi-
vidual bacteria (Engström et al., 2015). However, it was unclear
whether KSK120 affected inclusion size, bacterial replication or
both. Therefore, in this study we  quantiﬁed inclusion areas in the
presence or absence of compound KSK120. We have included C. tra-
chomatis serovar LGV-2 and serovar D in these experiments, which
both cause urogenital infections. It is well known that C. tracho-
matis inclusions can fuse if two bacteria infect a single host cell.
Therefore, we used a MOI  of 0.5, to minimize the inﬂuence of inclu-
sion fusion in our analysis. The compound was added immediately
following HeLa cell infection and inclusion areas were measured
at 48 and 60 hpi. Quantiﬁcation of inclusion areas was  possible
through a combination of obtained transmission images that visu-
alized the inclusion membrane and bacterial markers that labeled
C. trachomatis (Fig. 1A). At 48 hpi, we  observed a modest reduc-
tion in inclusion sizes of serovar D (15%) whereas the reduction
was more pronounced in LGV-2 (28%). Because inclusions in non-
treated infected cells began to lyse after 48 hpi, but inclusions
in KSK120-treated infections remained intact, it was difﬁcult to
compare inclusion areas between KSK120-treated and non-treated
infections at 60 hpi. Nonetheless, at 60 hpi, we  observed that inclu-
sion areas in KSK120-treated infections were signiﬁcantly larger
compared to KSK120-treated infections at 48 hpi (Fig. 1B). In addi-
tion, at 60 hpi, we observed that KSK120-treated infections had
larger inclusions compared to DMSO-treated infections at 48 hpi.
Together, these data suggest that KSK120-treatment slightly but
signiﬁcantly delays expansion of C. trachomatis inclusions.
To assess if KSK120 impaired bacterial replication we  quanti-
ﬁed genome equivalents at 48 hpi using qPCR and determined that
KSK120 strongly inhibited replication of LGV-2 (10-fold reduction,
Fig. 1C), and to a lesser extent serovar D (∼3-fold reduction, Fig. 1C).
Thus, we  concluded that KSK120 affects C. trachomatis replication.
Intriguingly, whereas KSK120 extensively reduced C. trachomatis
replication it did not reduce the size of inclusion areas to the same
extent (i.e. for LGV-2 at 48 hpi, genomic DNA was reduced by 90%
while inclusion sizes were only reduced by 28%), indicating that
bacterial replication is not a major determinant of inclusion expan-
sion.
Inclusion expansion is dependent on protein synthesis but not C.
trachomatis replication
Our previous data indicated that inclusion expansion did not
necessarily depend on bacterial replication, however it was unclear
if inclusions could expand in the absence of bacterial replication.
To assess if inclusions could expand in the absence of C. tracho-
matis replication, we quantiﬁed genomic DNA and inclusion area
sizes, in the presence or absence of KSK120 at different time points.
Samples were collected at 24, 36 and 48 hpi. In control-treated
infections an increase in bacterial replication correlated with larger
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Fig. 1. KSK120 reduces bacterial replication and delays expansion of formed inclusions. (A) HeLa cells infected with C. trachomatis serovars LGV-2 (MOI:  0.5) were treated
throughout the entire infection with 10 M KSK120 or DMSO, ﬁxed with methanol at 48 and 60 hpi, and stained with a MOMP  antibody (red) and HSP60 antibody (green).
DAPI  was  used to detect bacterial and host DNA (blue). Using identical settings, confocal laser scanning microscopy images were obtained, and inclusion membranes were
visualized with a 440 nm diode laser and a speciﬁc transmission detector channel. Inclusion membrane boundaries were manually traced (red), and inclusion areas (m2) were
quantiﬁed using EZ-C1 software (Nikon). (B) The area of 80–100 inclusions was  measured at 48 hpi and 60 hpi, treated with 10 M KSK120 or DMSO, which was  arbitrarily set
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to  1 for each C. trachomatis serovar. Statistical differences in inclusion areas were de
s,  not signiﬁcant. (C) Relative amounts of C. trachomatis DNA (48 hpi) was  quantiﬁ
mount of DNA in the DMSO treated infections was set to 1 for each C. trachomatis 
nclusion size (Fig. 2A–C), suggesting that under normal cell culture
onditions, inclusion expansion and bacterial replication occur in
arallel. In KSK120-treated infections, inclusions sizes were sim-
lar to control-treated infections. However, bacterial replication
as signiﬁcantly blocked in KSK120-treated infections after 24 hpi
Fig. 2A–C). These data show that C. trachomatis serovar LGV-2
nclusions can expand without replicating bacteria, arguing that
hese two processes are not necessarily coupled. To assess if bac-
erial de novo protein synthesis was required for expansion of
he formed inclusion, we supplemented the bacterial translational
nhibitor Cml  to cells at 24 hpi. Cml  blocked both bacterial replica-
ion and inclusion expansion (Fig. 2A–C), suggesting that protein
ynthesis is required for chlamydial inclusion expansion, corrob-
rating a recent observation (Gonzalez et al., 2014). Together,
hese data suggest that the C. trachomatis inclusion can expand in
he absence of bacterial replication. It would be ideal to have anned using the Mann–Whitney U test, *P < 0.05, **P < 0.01, ****P < 0.0001, two-tailed,
ng qPCR; infected cells were treated with 10 M KSK120 or DMSO, and the relative
r. ***P < 0.001 (unpaired student T-test, two-tailed). Error bars indicate SD.
antibiotic that only targets chlamydial replication to validate if C.
trachomatis replication is entirely dispensable for inclusion expan-
sion. To the best of our knowledge, current antibiotics that target C.
trachomatis replication also affect chlamydial transcription and/or
viability of the host cell. Furthermore, the possibility that KSK120
increases the accumulation of osmotically active compounds inside
inclusions, which would cause inclusions to expand in the absence
of C. trachomatis replication, cannot be completely excluded. How-
ever this scenario appears unlikely, as size and morphology of
individual bacteria is not affected by KSK120-treatment.
Our previous data showed that KSK120 blocked C. trachomatis
infectivity by targeting bacterial glucose metabolism (Engström
et al., 2015). Because C. trachomatis has a complex developmental
cycle, which includes its transition between an infectious elemen-
tary body (EB) and a replicative reticulate body (RB), the blockade
of infectivity caused by KSK120 could potentially be explained by:
P. Engström et al. / International Journal of Medical Microbiology 305 (2015) 378–382 381
Fig. 2. Expansion of formed C. trachomatis serovar LGV-2 inclusions is dependent on de novo protein synthesis but not bacterial replication. (A) C. trachomatis LGV-2 infected
HeLa  cells (MOI: 0.5) were treated with 10 M KSK120 or DMSO during the entire cycle of infection, 200 g/ml of chloramphenicol (Cml) were added to the indicated samples
at  24 hpi. At 24, 36 and 48 hpi, infected cells were ﬁxed and subsequently stained with antibodies generated against MOMP (red) and Hsp60 (green). DAPI was used to stain
bacterial and host DNA (blue). Using identical settings, images were produced using confocal laser microscopy and processed with Photoshop. Transmission images are
included to clarify how we traced the inclusion boundaries for subsequent quantiﬁcation. Arrows indicate inclusion membranes. (B) Mean inclusion areas were calculated
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1) generated EBs which have reduced infectivity, (2) altered RB-
B transition, and/or (3) KSK120 affects bacterial replication. In this
aper we observed that replication was blocked after 24 hpi, sug-
esting that the inhibitory effect of KSK120 on bacterial replication
as delayed (Fig. 2B), therefore, glucose metabolism may, at least
nder these experimental conditions, be important for progression
f C. trachomatis replication.
The data presented in this paper suggest that protein synthesis
s required for proper expansion of C. trachomatis serovar LGV-2
nclusions whereas bacterial replication is not. This is consistent
ith the observations that Coxiella and Legionella require protein
ynthesis but not bacterial replication for vacuole expansion (Coers
t al., 1999; Howe et al., 2003). All together, this suggests that vac-
ole size is an inadequate measure for quantifying intracellular
acterial replication and growth. Therefore, it is likely not appro-
riate to use inclusion size as a correlate for infectious progeny
utput (Ouellette and Carabeo, 2010), as we herein observe that 1. (C) Relative amounts of C. trachomatis DNA were (24, 36 and 48 hpi) measured
mic DNA from DMSO treated C. trachomatis at 24 hpi were arbitrarily set to 1. Error
the inclusions expand during almost complete absence of infec-
tious progeny generation (10 M KSK120, Fig. 2B and Engström
et al., 2015).
Conclusions
This study further characterizes the effect of the glucose
inhibitor KSK120 on C. trachomatis infections and reveals novel
information about C. trachomatis inclusion expansion. To the
best of our knowledge, our report is the ﬁrst to show that
C. trachomatis inclusions can expand without bacterial replica-
tion. This is important knowledge because inclusion size is a
commonly used measure for C. trachomatis replication and our
study suggests that this measurement is an inadequate esti-
mate of bacterial replication. In addition, current progress in
chlamydial genetic manipulation could result in mutant strains
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ith phenotypes resembling the effects of KSK120-treatment.
uch mutants could uncover potential bacterial effectors and
omponents that play a role in supporting late phase bac-
erial replication during an infection. Finally, we  believe that
his study further emphasizes the utility of chemical biology
pproaches in exploring obligate intracellular pathogen biol-
gy.
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